Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) COGS-to-Revenue : 0.52 (As of Mar. 2025)

View and export this data going back to 1998. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue?

Shanghai Fosun Pharmaceutical (Group) Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥4,920 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥9,420 Mil.

Shanghai Fosun Pharmaceutical (Group) Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.52.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Shanghai Fosun Pharmaceutical (Group) Co's Gross Margin % for the three months ended in Mar. 2025 was 47.77%.

Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.45

0.52

0.53

0.52

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.50	0.52	0.52	0.54	0.52

Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue Calculation

Shanghai Fosun Pharmaceutical (Group) Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	21365.574	/	41067.196
	=	0.52

Shanghai Fosun Pharmaceutical (Group) Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4920.296	/	9420.323
	=	0.52

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Shanghai Fosun Pharmaceutical (Group) Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	4920.296 / 9420.323
	=	47.77 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (SHSE:600196) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

SFOSF:USA 02196:Hong Kong 08HH:Germany 08HH:Germany

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.

Executives

Yao Fang	Director
Wu Yi Fang	Director
Wen De Yong	Directors, senior managers
Guan Xiao Hui	Director
Wang Ke Xin	Director
Bao Qin Gui	senior management
Mei Jing Ping	senior management
Li Sheng Li	senior management
Feng Rong Li	senior management
Wang Dong Hua	senior management
Dong Xiao Xian	senior management
Su Li	senior management
Zhu Yue	senior management
Chen Yu Qing	senior management
Hu Hang	senior management

Shanghai Fosun Pharmaceutical (Group) Co Headlines

No Headlines